Literature DB >> 28300577

PGE2 synthesis and signaling in malignant transformation and progression of human hepatocellular carcinoma.

Shengbing Zang1, Xiaojie Ma2, Yanbin Wu3, Wenwen Liu1, Haili Cheng1, Jiasi Li1, Jingfeng Liu3, Aimin Huang4.   

Abstract

Prostaglandin E 2 (PGE2), which is the most abundant prostaglandin produced in hepatocellular carcinoma (HCC), may be involved in hepatocarcinogenesis. Here, the amount of PGE2 was significantly increased in HCC tissue and adjacent noncancerous tissues relative to normal liver tissue (P<.001). In addition, the expression of EP2 receptor was considerably upregulated in HCC tissue compared with the expression of EP1 (P<.05), EP3 (P<.01), and EP4 (P<.01) receptor. The expression of EP2 receptor was positively correlated with the level of PGE2 in HCC tissue (P<.001). Furthermore, PGE2 significantly increased proliferation and invasion potential of human HCC cells. However, antagonism of EP2 signaling suppressed PGE2-induced growth and invasion in human HCC cells. Taken together, upregulation of PGE2 level was associated with proliferation and invasion potential of HCC, and EP2 receptor predominately mediated the function of PGE2 in the transformation and progression of HCC.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antagonism; E prostanoid receptor; Hepatocellular carcinoma; Proliferation; Prostaglandin E 2 (PGE(2))

Mesh:

Substances:

Year:  2017        PMID: 28300577     DOI: 10.1016/j.humpath.2017.02.018

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Exposure to growth hormone is associated with hepatic up-regulation of cPLA2α and COX.

Authors:  Verónica G Piazza; María E Matzkin; Nadia S Cicconi; Nadia V Muia; Sofía Valquinta; Gregorio J Mccallum; Giannina P Micucci; Thomas Freund; Elsa Zotta; Lorena González; Mónica B Frungieri; Yimin Fang; Andrzej Bartke; Ana I Sotelo; Johanna G Miquet
Journal:  Mol Cell Endocrinol       Date:  2020-04-04       Impact factor: 4.102

2.  Prediagnostic levels of urinary 8-epi-prostaglandin F2α and prostaglandin E2 metabolite, biomarkers of oxidative damage and inflammation, and risk of hepatocellular carcinoma.

Authors:  Jian-Min Yuan; Menno Grouls; Steven G Carmella; Renwei Wang; Alisa Heskin; Yang Jiang; Yu-Ting Tan; Jennifer Adams-Haduch; Yu-Tang Gao; Stephen S Hecht
Journal:  Carcinogenesis       Date:  2019-08-22       Impact factor: 4.944

3.  GRK2 Suppresses Hepatocellular Carcinoma Metastasis and Invasion Through Down-Regulation of Prostaglandin E Receptor 2.

Authors:  Nan Li; Jing-Jing Wu; Ting-Ting Chen; Xiu-Qin Li; Jia-Jia Du; Shan Shan; Wei Wei; Wu-Yi Sun
Journal:  Onco Targets Ther       Date:  2020-09-28       Impact factor: 4.147

Review 4.  Targeting the eicosanoid pathway in hepatocellular carcinoma.

Authors:  Anshuli Razdan; Nathan M Main; Vincent Chiu; Nicholas A Shackel; Paul de Souza; Katherine Bryant; Kieran F Scott
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

Review 5.  Prostaglandin Pathways: Opportunities for Cancer Prevention and Therapy.

Authors:  Qiushi Wang; Rebecca J Morris; Ann M Bode; Tianshun Zhang
Journal:  Cancer Res       Date:  2022-03-15       Impact factor: 13.312

Review 6.  Prostaglandin E2 and Receptors: Insight Into Tumorigenesis, Tumor Progression, and Treatment of Hepatocellular Carcinoma.

Authors:  Chao Chen; Jun Guan; Xinyu Gu; Qingfei Chu; Haihong Zhu
Journal:  Front Cell Dev Biol       Date:  2022-03-10

Review 7.  Anti-Cancer and Protective Effects of Royal Jelly for Therapy-Induced Toxicities in Malignancies.

Authors:  Yasuyoshi Miyata; Hideki Sakai
Journal:  Int J Mol Sci       Date:  2018-10-21       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.